1
|
Pires PC, Damiri F, Zare EN, Hasan A, Neisiany RE, Veiga F, Makvandi P, Paiva-Santos AC. A review on natural biopolymers in external drug delivery systems for wound healing and atopic dermatitis. Int J Biol Macromol 2024; 263:130296. [PMID: 38382792 DOI: 10.1016/j.ijbiomac.2024.130296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2023] [Revised: 02/14/2024] [Accepted: 02/17/2024] [Indexed: 02/23/2024]
Abstract
Despite the advantages of topical administration in the treatment of skin diseases, current marketed preparations face the challenge of the skin's barrier effect, leading to low therapeutic effectiveness and undesirable side effects. Hence, in recent years the management of skin wounds, the main morbidity-causing complication in hospital environments, and atopic dermatitis, the most common inflammatory skin disease, has become a great concern. Fortunately, new, more effective, and safer treatments are already under development, with chitosan, starch, silk fibroin, agarose, hyaluronic acid, alginate, collagen, and gelatin having been used for the development of nanoparticles, liposomes, niosomes and/or hydrogels to improve the delivery of several molecules for the treatment of these diseases. Biocompatibility, biodegradability, increased viscosity, controlled drug delivery, increased drug retention in the epidermis, and overall mitigation of adverse effects, contribute to an effective treatment, additionally providing intrinsic antimicrobial and wound healing properties. In this review, some of the most recent success cases of biopolymer-based drug delivery systems as part of nanocarriers, semi-solid hydrogel matrices, or both (hybrid systems), for the management of skin wounds and atopic dermatitis, are critically discussed, including composition and in vitro, ex vivo and in vivo characterization, showing the promise of these external drug delivery systems.
Collapse
Affiliation(s)
- Patrícia C Pires
- Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal; REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal; Health Sciences Research Centre (CICS-UBI), University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal
| | - Fouad Damiri
- Laboratory of Biomolecules and Organic Synthesis (BIOSYNTHO), Department of Chemistry, Faculty of Sciences Ben M'Sick, University Hassan II of Casablanca, Casablanca, Morocco; Chemical Science and Engineering Research Team (ERSIC), Department of Chemistry, Polydisciplinary Faculty of Beni Mellal (FPBM), University Sultan Moulay Slimane (USMS), Beni Mellal 23000, Morocco
| | - Ehsan Nazarzadeh Zare
- School of Chemistry, Damghan University, Damghan 36716-45667, Iran; Centre of Research Impact and Outcome, Chitkara University, Rajpura-140401, Punjab, India
| | - Anwarul Hasan
- Department of Mechanical and Industrial Engineering, Qatar University, Doha 2713, Qatar; Biomedical Research Center, Qatar University, Doha 2713, Qatar.
| | - Rasoul Esmaeely Neisiany
- Biotechnology Centre, Silesian University of Technology, Krzywoustego 8, 44-100 Gliwice, Poland; Department of Polymer Engineering, Hakim Sabzevari University, Sabzevar 9617976487, Iran
| | - Francisco Veiga
- Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal; REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal
| | - Pooyan Makvandi
- Institute for Bioengineering, School of Engineering, The University of Edinburgh, Edinburgh, UK; Chitkara Centre for Research and Development, Chitkara University, Himachal Pradesh 174103, India; Department of Biomaterials, Saveetha Dental College and Hospitals, SIMATS, Saveetha University, Chennai 600077, India
| | - Ana Cláudia Paiva-Santos
- Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal; REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Coimbra, Portugal.
| |
Collapse
|
2
|
Pareek A, Kumari L, Pareek A, Chaudhary S, Ratan Y, Janmeda P, Chuturgoon S, Chuturgoon A. Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives. Cells 2024; 13:425. [PMID: 38474389 DOI: 10.3390/cells13050425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/24/2024] [Accepted: 02/26/2024] [Indexed: 03/14/2024] Open
Abstract
Atopic dermatitis (AD) is an inflammatory skin condition that frequently develops before the onset of allergic rhinitis or asthma. More than 10% of children are affected by this serious skin condition, which is painful for the sufferers. Recent research has connected the environment, genetics, the skin barrier, drugs, psychological factors, and the immune system to the onset and severity of AD. The causes and consequences of AD and its cellular and molecular origins are reviewed in this paper. The exploration of interleukins and their influence on the immunological pathway in AD has been facilitated by using relevant biomarkers in clinical trials. This approach enables the identification of novel therapeutic modalities, fostering the potential for targeted translational research within the realm of personalized medicine. This review focuses on AD's pathophysiology and the ever-changing therapeutic landscape. Beyond the plethora of biologic medications in various stages of approval or development, a range of non-biologic targeted therapies, specifically small molecules, have emerged. These include Janus kinase (JAK) inhibitors like Baricitinib, Upadacitinib, and Abrocitinib, thus expanding the spectrum of therapeutic options. This review also addresses the latest clinical efficacy data and elucidates the scientific rationale behind each targeted treatment for atopic dermatitis.
Collapse
Affiliation(s)
- Ashutosh Pareek
- Department of Pharmacy, Banasthali Vidyapith, Banasthali 304022, India
| | - Lipika Kumari
- Department of Bioscience and Biotechnology, Banasthali Vidyapith, Banasthali 304022, India
| | - Aaushi Pareek
- Department of Pharmacy, Banasthali Vidyapith, Banasthali 304022, India
| | - Simran Chaudhary
- Department of Pharmacy, Banasthali Vidyapith, Banasthali 304022, India
| | - Yashumati Ratan
- Department of Pharmacy, Banasthali Vidyapith, Banasthali 304022, India
| | - Pracheta Janmeda
- Department of Bioscience and Biotechnology, Banasthali Vidyapith, Banasthali 304022, India
| | - Sanam Chuturgoon
- Northdale Hospital, Department of Health, Pietermaritzburg 3200, South Africa
| | - Anil Chuturgoon
- Discipline of Medical Biochemistry, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4041, South Africa
| |
Collapse
|
3
|
Dawoud MHS, Mannaa IS, Abdel-Daim A, Sweed NM. Integrating Artificial Intelligence with Quality by Design in the Formulation of Lecithin/Chitosan Nanoparticles of a Poorly Water-Soluble Drug. AAPS PharmSciTech 2023; 24:169. [PMID: 37552427 DOI: 10.1208/s12249-023-02609-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Accepted: 06/25/2023] [Indexed: 08/09/2023] Open
Abstract
The aim of the current study is to explore the potential of artificial intelligence (AI) when integrated with Quality by Design (QbD) approach in the formulation of a poorly water-soluble drug, for its potential use in carcinoma. Silymarin is used as a model drug for its potential effectiveness in liver cancer. A detailed QbD approach was applied. The effect of the critical process parameters was studied on each of the particle size, size distribution, and entrapment efficiency. Response surface designs were applied in the screening and optimization of lecithin/chitosan nanoparticles, to obtain an optimized formula. The release rate was tested, where artificial neural network models were used to predict the % release of the drug from the optimized formula at different time intervals. The optimized formula was tested for its cytotoxicity. A design space was established, with an optimized formula having a molar ratio of 18.33:1 lecithin:chitosan and 38.35 mg silymarin. This resulted in nanoparticles with a size of 161 nm, a polydispersity index of 0.2, and an entrapment efficiency of 97%. The optimized formula showed a zeta potential of +38 mV, with well-developed spherical particles. AI successfully showed high prediction ability of the drug's release rate. The optimized formula showed an enhancement in the cytotoxic effect of silymarin with a decreased IC50 compared to standard silymarin. Lecithin/chitosan nanoparticles were successfully formulated, with deep process and product understanding. Several tools were used as AI which could shift pharmaceutical formulations from experience-dependent studies to data-driven methodologies in the future.
Collapse
Affiliation(s)
- Marwa H S Dawoud
- Department of Pharmaceutics, Faculty of Pharmacy, October University for Modern Sciences and Arts, intersection of 26th of July road and Elwahat road, 6th of October city, Giza, Egypt.
| | - Islam S Mannaa
- Department of Pharmaceutics, Faculty of Pharmacy, October University for Modern Sciences and Arts, intersection of 26th of July road and Elwahat road, 6th of October city, Giza, Egypt
| | - Amira Abdel-Daim
- Department of Biochemistry, Faculty of Pharmacy, October University for Modern Sciences and Arts, Giza, Egypt
| | - Nabila M Sweed
- Department of Pharmaceutics, Faculty of Pharmacy, October University for Modern Sciences and Arts, intersection of 26th of July road and Elwahat road, 6th of October city, Giza, Egypt
| |
Collapse
|
4
|
Rapidly Dissolving Microneedles for the Delivery of Steroid-Loaded Nanoparticles Intended for the Treatment of Inflammatory Skin Diseases. Pharmaceutics 2023; 15:pharmaceutics15020526. [PMID: 36839849 PMCID: PMC9967926 DOI: 10.3390/pharmaceutics15020526] [Citation(s) in RCA: 15] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Revised: 01/21/2023] [Accepted: 02/02/2023] [Indexed: 02/08/2023] Open
Abstract
Drug delivery through the skin has immense advantages compared to other routes of administration and offers an optimal way to treat inflammatory skin diseases, where corticosteroids are the cornerstone of topical therapy. Still, their therapeutic efficiency is limited due to inadequate skin permeability, potential side effects, and reduced patient compliance. To overcome these drawbacks, we propose a drug delivery system consisting of dexamethasone (DEX)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) incorporated in sodium alginate (SA) microneedles (MNs) as a minimally invasive dosage form for controlled drug release. Drug-loaded PLGA NPs were prepared by a nanoprecipitation method with a high encapsulation yield. They exhibited a controlled release pattern over 120 h. A modified vacuum-deposition micromolding method was used to load the obtained DEX-NPs into the tips of dissolving MNs. The NP-MNs showed improved insertion capabilities into the skin-simulant parafilm model and enhanced mechanical strength when tested against different static forces compared to their counterparts (SA-MNs). The results of an MN dissolution study following application to ex vivo chicken skin and agarose gel indicate that the NP-loaded segments of MNs dissolve within 15 s, in which the NPs are released into the skin. Taken together, the incorporation of DEX-NPs into SA-MNs could be a promising approach to bypass the limitations of conventional topical treatment of skin diseases, allowing for self-administration, increased patient compliance, and controlled drug release.
Collapse
|
5
|
Polymer-based biomaterials for pharmaceutical and biomedical applications: a focus on topical drug administration. Eur Polym J 2023. [DOI: 10.1016/j.eurpolymj.2023.111868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
|
6
|
Kumar P, Ashawat MS, Pandit V, Singh Verma CP, Ankalgi AD, Kumar M. Recent Trends in Nanocarriers for the Management of Atopic Dermatitis. Pharm Nanotechnol 2023; 11:397-409. [PMID: 36998138 DOI: 10.2174/2211738511666230330115229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Revised: 01/07/2023] [Accepted: 01/25/2023] [Indexed: 04/01/2023]
Abstract
BACKGROUND Atopic dermatitis (AD) is a pruritic inflammatory skin condition with increasing global prevalence, almost affecting 15% to 30% of children and 5% of adults. AD results due to a complex interaction between the impaired skin barrier function, allergens, and immunological cells. Topical corticosteroids or calcineurin inhibitors in the form of creams or ointments are the mainstay of therapy, but they have low skin penetration and skin barrier repair efficiency. OBJECTIVE The above limitations of conventional dosage forms have motivated the development of nanoformulations of drugs for improved penetration and deposition in the skin for better management of AD. METHODS Databases, such as Pubmed, Elsevier, and Google Scholar, were reviewed for the investigations or reviews published related to the title. RESULTS The present review discusses the advantages of nanoformulations for the management of AD. Further, it also discusses the various types of topically investigated nanoformulations, i.e., polymeric nanoparticles, inorganic nanoparticles, solid lipid nanoparticles, liposomes, ethosomes, transfersomes, cubosomes, and nanoemulsion for the management of atopic dermatitis. In addition, it also discusses advancements in nanoformulations, such as nanofibres, nanosponges, micelles, and nanoformulations embedded textiles development for the management of AD. CONCLUSION The nanoformulations of drugs can be a better alternative for the topical management of AD with enhanced skin penetration and deposition of drugs with reduced systemic side effects and better patient compliance.
Collapse
Affiliation(s)
- Pravin Kumar
- Laureate Institute of Pharmacy, VPO-Kathog, Jwalamukhi, Kangra, H.P, 176031, India
| | | | - Vinay Pandit
- Laureate Institute of Pharmacy, VPO-Kathog, Jwalamukhi, Kangra, H.P, 176031, India
| | | | - Amar Deep Ankalgi
- Laureate Institute of Pharmacy, VPO-Kathog, Jwalamukhi, Kangra, H.P, 176031, India
| | - Manish Kumar
- M.M. College of Pharmacy, Maharshi Markendeshwar (Deemed to be University), Mullana, Ambala, Haryana, India
| |
Collapse
|
7
|
Liu L, Ma Q, Wang S, Gao Y, Zhu C, Zhao W, Sun W, Ma H, Sun Y. Efficient epidermal delivery of antibiotics by self-assembled lecithin/chitosan nanoparticles for enhanced therapy on epidermal bacterial infections. Int J Biol Macromol 2022; 218:568-579. [PMID: 35902014 DOI: 10.1016/j.ijbiomac.2022.07.165] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 07/20/2022] [Accepted: 07/20/2022] [Indexed: 11/30/2022]
Abstract
The treatment for epidermal bacterial infections has become a primary healthy concern, producing a significant therapeutic challenge. Here we present a facile strategy to fabricate lecithin/chitosan nanoparticles (LCNPs) for efficient epidermal drug delivery over epidermal bacterial infections. The central rotatable composite design method was used for the optimization of the preparation, and that the optimal size (212.63 ± 1.95 nm) was obtained via analysis of variance (ANOVA). The prepared CIP-LCNPs show an average diameter of 325.9 ± 7.4 nm and a zeta potential of 26.6 ± 1.2 mV. Antibiotics can be well encapsulated in LCNPs and its release kinetics is studied with cumulative release of 93.81 ± 2.05 % for 48 h. The hemolytic activity, cytotoxicity, and skin irritation are further investigated. The zones of inhibition are 2.16 ± 0.04 cm and 2.92 ± 0.03 cm for Escherichia coli and Staphylococcus aureus, respectively. Moreover, in vitro permeation studies demonstrate that LCNPs can increase the accumulation of antibiotics in the epidermis with retention ratio 2-3 fold higher than commercial formulations. The in vivo result over epidermal-infected wound demonstrates the superior therapeutic effects of LCNPs. The developed LCNPs represent an important advance in fabricating therapeutic materials for enhanced therapy over epidermal bacterial infections.
Collapse
Affiliation(s)
- Lijun Liu
- School of Pharmacy, Qingdao University, Qingdao 266071, China
| | - Qingming Ma
- School of Pharmacy, Qingdao University, Qingdao 266071, China.
| | - Suning Wang
- Tongliao Market Detection and Testing Center, Tongliao 028000, China
| | - Yang Gao
- School of Pharmacy, Qingdao University, Qingdao 266071, China
| | - Chunrong Zhu
- School of Pharmacy, Qingdao University, Qingdao 266071, China
| | - Wenbin Zhao
- School of Pharmacy, Qingdao University, Qingdao 266071, China
| | - Wentao Sun
- School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao 266113, China.
| | - Haifeng Ma
- Department of Geriatrics, Zibo Municipal Hospital, Zibo 255400, China.
| | - Yong Sun
- School of Pharmacy, Qingdao University, Qingdao 266071, China.
| |
Collapse
|
8
|
Cláudia Paiva-Santos A, Gama M, Peixoto D, Sousa-Oliveira I, Ferreira-Faria I, Zeinali M, Abbaspour-Ravasjani S, Mascarenhas-Melo F, Hamishehkar H, Veiga F. Nanocarrier-based dermopharmaceutical formulations for the topical management of atopic dermatitis. Int J Pharm 2022; 618:121656. [DOI: 10.1016/j.ijpharm.2022.121656] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 02/17/2022] [Accepted: 03/07/2022] [Indexed: 01/23/2023]
|
9
|
Yousfan A, Rubio N, Al-Ali M, Nattouf AH, Kafa H. Intranasal delivery of phenytoin-loaded nanoparticles to the brain suppresses pentylenetetrazol-induced generalized tonic clonic seizures in an epilepsy mouse model. Biomater Sci 2021; 9:7547-7564. [PMID: 34652351 DOI: 10.1039/d1bm01251g] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
In this work we describe the preparation and characterization of lecithin-chitosan nanoparticles (L10Ci+), and investigate their ability to deliver the anti-epileptic drug phenytoin (PHT) to mouse brain following intranasal (IN) administration. L10Ci+ were retained in the nasal cavity compared to PHT in PEG200 solution (PHT/PEG), which suffered immediate nasal drainage. PHT was detected in the brain after 5 min of IN administration reaching a maximum of 11.84 ± 2.31 %ID g-1 after 48 hours. L10Ci+ were associated with a higher brain/plasma ratio (Cb/p) compared to the experimental control comprising free PHT injected via the intraperitoneal route (PHT-IP) across all tested time points. Additionally, L10Ci+ led to lower PHT accumulation in the liver and spleen compared to PHT-IP, which is vital for lowering the systemic side effects of PHT. The relatively high drug targeting efficiency (DTE%) of 315.46% and the drug targeting percentage (DTP%) of 68.29%, combined with the increasing anterior-to-posterior gradient of PHT in the brain confirmed the direct nose-to-brain transport of PHT from L10Ci+. Electroencephalogram (EEG) analysis was used to monitor seizure progression. L10Ci+ resulted in a complete seizure suppression after 4 hours of administration, and this inhibition persisted even with an 8-fold reduction of the encapsulated dose compared to the required PHT-IP dose to achieve a similar inhibitory effect due to systemic loss. The presented findings confirm the possibility of using L10Ci+ as a non-invasive delivery system of PHT for the management of epilepsy using reduced doses of PHT.
Collapse
Affiliation(s)
- Amal Yousfan
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Syria
| | - Noelia Rubio
- Department of Chemistry and Materials, Imperial College London, SW7 2AZ, UK
| | - Mohammad Al-Ali
- Department of Molecular Biology and Biotechnology, Atomic Energy Commission of Syria, Damascus, Syria.
| | - Abdul Hakim Nattouf
- Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University, Syria
| | - Houmam Kafa
- Department of Molecular Biology and Biotechnology, Atomic Energy Commission of Syria, Damascus, Syria.
| |
Collapse
|
10
|
Shetty K, Sherje AP. Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitis-a systematic review. JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE 2021; 32:88. [PMID: 34331599 PMCID: PMC8325647 DOI: 10.1007/s10856-021-06558-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Accepted: 07/07/2021] [Indexed: 05/03/2023]
Abstract
Atopic dermatitis (AD) and psoriasis are highly prevalent, complex, chronic inflammatory skin diseases that immensly affect the patient's quality of life. While there is no definitive cure for these conditions, suppressive medications aim at managing the symptoms of these diseases. The application of emollients accompanied by symptomatic anti-inflammatory therapy consisting of topical corticosteroids (TCS) is extensively employed for controlling the symptoms among general practitioners making this therapeutic class an indispensable pillar of dermatotherapeutics. The first TCS, hydrocortisone (HC) introduced in the early 1950s led to the development of different steroidal moieties of varying potencies by inducing chemical modifications to the basic steroid structure. The wide spectrum of the available range of formulations and potency provides flexibility to treat all patient groups, different phases of the diseases, and different anatomical sites. Conventional TCS therapy suffers from drawbacks such as low drug permeation and retention rate. Thus, novel nanoformulations have been developed to overcome these problems. This review provides an insight into the current state of nanocarrier-mediated topical delivery of corticosteroids monotherapy and combination therapy with special emphasis on targeting psoriasis and AD.
Collapse
Affiliation(s)
- Kshitya Shetty
- SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, 400 056, India
| | - Atul P Sherje
- SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, 400 056, India.
| |
Collapse
|
11
|
Nanoemulsion loaded polymeric hydrogel for topical delivery of curcumin in psoriasis. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.101847] [Citation(s) in RCA: 33] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
12
|
Bacterially sensitive nanoparticle-based dissolving microneedles of doxycycline for enhanced treatment of bacterial biofilm skin infection: A proof of concept study. INTERNATIONAL JOURNAL OF PHARMACEUTICS-X 2020; 2:100047. [PMID: 32322819 PMCID: PMC7168771 DOI: 10.1016/j.ijpx.2020.100047] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Revised: 03/02/2020] [Accepted: 03/08/2020] [Indexed: 02/07/2023]
Abstract
The presence of bacterial biofilms in wounds is a main issue in the healing process. Conventional therapy of bacterial biofilms is hampered by the poor penetration of antibacterial agents through the physical barrier on the infected skin and the non-specific target of antibacterial agents. Here, we present a combination approach of bacterial sensitive nanoparticles (NPs) and dissolving microneedles (MNs) of doxycycline (DOX) for improved biofilm penetration and specifically delivering DOX to the infection site. The NPs were prepared from poly(lactic-co-glycolic acid) and poly (Ɛ-caprolactone) decorated with chitosan. The release of DOX was improved with the presence of bacterial producing biofilm up to 7-fold. The incorporation of these NPs into dissolving MNs was able to significantly enhance the dermatokinetic profiles of DOX, indicated by higher retention time compared to needle-free patches. Importantly, the antibiofilm activity in ex vivo biofilm model showed that after 48 h, the bacterial bioburdens decreased up to 99.99% following the application of this approach. The results presented here assist as proof of principle for the improvement of dermatokinetic profiles and antibiofilm activities of DOX, following its formulation into bacterial sensitive NPs and delivery via MN. Future studies must explore in vivo efficacy in a suitable animal model.
Collapse
|
13
|
Dian Permana A, Mir M, Utomo E, Donnelly RF. WITHDRAWN: Bacterially sensitive nanoparticle-based dissolving microneedles of doxycycline for enhanced treatment of bacterial biofilm skin infection: A proof of concept study. Int J Pharm 2020:119220. [PMID: 32165225 DOI: 10.1016/j.ijpharm.2020.119220] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Revised: 03/02/2020] [Accepted: 03/08/2020] [Indexed: 10/24/2022]
Affiliation(s)
- Andi Dian Permana
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast. BT9 7BL, UK; Department of Pharmaceutics, Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia
| | - Maria Mir
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast. BT9 7BL, UK; Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan
| | - Emilia Utomo
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast. BT9 7BL, UK
| | - Ryan F Donnelly
- School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast. BT9 7BL, UK.
| |
Collapse
|
14
|
Yousfan A, Rubio N, Natouf AH, Daher A, Al-Kafry N, Venner K, Kafa H. Preparation and characterisation of PHT-loaded chitosan lecithin nanoparticles for intranasal drug delivery to the brain. RSC Adv 2020; 10:28992-29009. [PMID: 35520085 PMCID: PMC9055806 DOI: 10.1039/d0ra04890a] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 07/20/2020] [Indexed: 12/18/2022] Open
Abstract
The use of nanoparticles (NPs) for intranasal (IN) drug delivery to the brain represents a hopeful strategy to enhance brain targeting of anti-epileptic drugs.
Collapse
Affiliation(s)
- Amal Yousfan
- Department of Pharmaceutics and Pharmaceutical Technology
- Pharmacy Collage
- Damascus University
- Syria
| | - Noelia Rubio
- Department of Chemistry and Materials
- Imperial College London
- London
- UK
| | - Abdul Hakim Natouf
- Department of Pharmaceutics and Pharmaceutical Technology
- Pharmacy Collage
- Damascus University
- Syria
| | - Aamal Daher
- Department of Molecular Biology and Biotechnology
- Atomic Energy Commission of Syria
- Damascus
- Syria
| | - Nedal Al-Kafry
- Department of Molecular Biology and Biotechnology
- Atomic Energy Commission of Syria
- Damascus
- Syria
| | - Kerrie Venner
- Institute of Neurology
- University College London
- London
- UK
| | - Houmam Kafa
- Department of Molecular Biology and Biotechnology
- Atomic Energy Commission of Syria
- Damascus
- Syria
| |
Collapse
|
15
|
Targeted Therapeutic Nanoparticles: An Immense Promise to Fight against Cancer. JOURNAL OF DRUG DELIVERY 2017; 2017:9090325. [PMID: 29464123 PMCID: PMC5804325 DOI: 10.1155/2017/9090325] [Citation(s) in RCA: 66] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/14/2017] [Revised: 10/12/2017] [Accepted: 10/19/2017] [Indexed: 11/17/2022]
Abstract
In nanomedicine, targeted therapeutic nanoparticle (NP) is a virtual outcome of nanotechnology taking the advantage of cancer propagation pattern. Tying up all elements such as therapeutic or imaging agent, targeting ligand, and cross-linking agent with the NPs is the key concept to deliver the payload selectively where it intends to reach. The microenvironment of tumor tissues in lymphatic vessels can also help targeted NPs to achieve their anticipated accumulation depending on the formulation objectives. This review accumulates the application of poly(lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG) based NP systems, with a specific perspective in cancer. Nowadays, PLGA, PEG, or their combinations are the mostly used polymers to serve the purpose of targeted therapeutic NPs. Their unique physicochemical properties along with their biological activities are also discussed. Depending on the biological effects from parameters associated with existing NPs, several advantages and limitations have been explored in teaming up all the essential facts to give birth to targeted therapeutic NPs. Therefore, the current article will provide a comprehensive review of various approaches to fabricate a targeted system to achieve appropriate physicochemical properties. Based on such findings, researchers can realize the benefits and challenges for the next generation of delivery systems.
Collapse
|
16
|
Andrade LM, Silva LAD, Krawczyk-Santos AP, Amorim ICDS, Rocha PBRD, Lima EM, Anjos JLV, Alonso A, Marreto RN, Taveira SF. Improved tacrolimus skin permeation by co-encapsulation with clobetasol in lipid nanoparticles: Study of drug effects in lipid matrix by electron paramagnetic resonance. Eur J Pharm Biopharm 2017. [DOI: 10.1016/j.ejpb.2017.06.014] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
17
|
Gul R, Ahmed N, Shah KU, Khan GM, Asim Ur Rehman. Functionalised nanostructures for transdermal delivery of drug cargos. J Drug Target 2017; 26:110-122. [PMID: 28854819 DOI: 10.1080/1061186x.2017.1374388] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Nanotechnology has burgeoned over last decade exploring varieties of novel applications in all areas of science and technology. Utilisation of bio-friendly polymers for engineering nanostructures (NS) improves safety and efficacy in drug delivery. Biopolymers not merely employed for fabricating drug carriers but also leveraged for surface functionalisation of other NS to impart bio-mimicking properties. Biopolymer functionalised NS garnered researcher's attention because of their potential to enhance skin permeability of drug cargo. Biopolymers, i.e. cell-penetrating peptides (CPP), chitosan and hyaluronic acid not only enhance skin permeability but also add multiple functions due to their intrinsic biomimetic properties. This multifunctional drug delivery system is a promising tool to achieve skin delivery of large number of therapeutic agents. In this review, functionalisation of NS with biopolymers particularly polysaccharides and polypeptides is discussed in detail. In particular, applications of these functionalised NS for TDDS is elaborated. Moreover, this review provides framework for elaborating importance of functionalisation of NS to enhance skin permeability and depicts advantages of biopolymers to construct more biocompatible carriers for drug cargos.
Collapse
Affiliation(s)
- Rabia Gul
- a Department of Pharmacy , Quaid.i.Azam University , Islamabad , Pakistan
| | - Naveed Ahmed
- a Department of Pharmacy , Quaid.i.Azam University , Islamabad , Pakistan
| | - Kifayat Ullah Shah
- a Department of Pharmacy , Quaid.i.Azam University , Islamabad , Pakistan
| | - Gul Majid Khan
- a Department of Pharmacy , Quaid.i.Azam University , Islamabad , Pakistan
| | - Asim Ur Rehman
- a Department of Pharmacy , Quaid.i.Azam University , Islamabad , Pakistan
| |
Collapse
|
18
|
Debotton N, Badihi A, Robinpour M, Enk CD, Benita S. Dermal absorption behavior of fluorescent molecules in nanoparticles on human and porcine skin models. Int J Pharm 2017; 524:290-303. [DOI: 10.1016/j.ijpharm.2017.03.091] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2017] [Revised: 03/30/2017] [Accepted: 03/31/2017] [Indexed: 10/19/2022]
|
19
|
Sala M, Elaissari A, Fessi H. Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J Control Release 2016; 239:182-202. [PMID: 27381248 DOI: 10.1016/j.jconrel.2016.07.003] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2016] [Revised: 06/30/2016] [Accepted: 07/01/2016] [Indexed: 11/26/2022]
Abstract
Psoriasis is a chronic inflammatory disease affecting mainly the skin but which can be complicated by psoriatic arthritis (PsA).This autoimmune skin disorder concerns 2-5% of the world population. To date, the physiopathology of psoriasis is not still completely elucidated but many researches are ongoing which have led for example to the discovery of the Th17/Th22 pathway. The conventional therapeutic approaches (local or systemic route) appeal to various classes of drugs with complex mechanisms of action and non-negligible side effects. Although there is no therapy capable to cure psoriasis, the current goal is to relieve symptoms as longer as possible with a good benefit/risk ratio. That is one of the principal limits of conventional antipsoriatic drugs. New formulations based on nanoencapsulation are a promising opportunity to answer to this limit by offering an optimization of the conventional antipsoriatic drug use (higher activity, lower side effects and frequency of application, etc.). Herein, we tried to put in perspective the mechanistic insights (histological and immunological views) proposed into scientific literature these last years in order to have a better comprehension of psoriasis physiopathology resulting in skin lesions and PsA. The therapeutic armamentarium and the different strategies in the management of psoriasis are discussed in greater details. To finish, the field of encapsulation in nanoparticles is broached in order to put forward recent advances in innovative skin drug delivery systems (ISDDSs) of antipsoriatic active agents for a better efficacy, safety and compliance.
Collapse
Affiliation(s)
- M Sala
- University Claude Bernard Lyon 1, Laboratoire d'Automatique et de Génie des Procédés, CNRS, UMR 5007, LAGEP-CPE-308G, 43 bd. du 11 Nov.1918, F-69622 Villeurbanne, France; Pharmacie centrale, Hospices Civils de Lyon, 57, Rue Francisque Darcieux, 69563 Saint Genis Laval, France
| | - A Elaissari
- University Claude Bernard Lyon 1, Laboratoire d'Automatique et de Génie des Procédés, CNRS, UMR 5007, LAGEP-CPE-308G, 43 bd. du 11 Nov.1918, F-69622 Villeurbanne, France
| | - H Fessi
- University Claude Bernard Lyon 1, Laboratoire d'Automatique et de Génie des Procédés, CNRS, UMR 5007, LAGEP-CPE-308G, 43 bd. du 11 Nov.1918, F-69622 Villeurbanne, France.
| |
Collapse
|
20
|
Silva LAD, Andrade LM, de Sá FAP, Marreto RN, Lima EM, Gratieri T, Taveira SF. Clobetasol-loaded nanostructured lipid carriers for epidermal targeting. J Pharm Pharmacol 2016; 68:742-50. [DOI: 10.1111/jphp.12543] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2015] [Accepted: 02/14/2016] [Indexed: 11/29/2022]
Abstract
Abstract
Objectives
The aim of this study was to investigate in vitro the epidermal targeting potential of clobetasol propionate-loaded nanostructured lipid carriers (CP-NLC) when compared to that of chitosan-coated (CP-NLC-C).
Methods
CP-NLC were prepared by microemulsion method and characterized by dynamic light scattering, transmission electron microscopy, in vitro release and permeation studies. To verify epidermal targeting, permeation studies were performed in two sets of experiments. For the first set, the skin was removed from the diffusion cell and stratum corneum (SC) was separated from the remaining skin (RS). For the second set, the whole epidermis (EP) was separated from the dermis (DER). CP quantification was performed in each skin layer.
Key findings
A novel clobetasol propionate-loaded NLC was produced with 1/5th of the drug dose used in commercial formulations and, even so, presented greater skin permeation. Both chitosan-coated and uncoated NLC enhanced the amount of CP in the epidermis more than 80-fold when compared to the commercial formulation (20.26 ± 2.77; 17.85 ± 0.49 and 0.22 ± 0.02 μg/cm2, respectively). Differently from chitosan-coated NLC, the uncoated NLC did not show dermal retention.
Conclusions
NLC proved to be a system with potential for targeting drug delivery to the epidermal layer.
Collapse
Affiliation(s)
- Luis Antônio Dantas Silva
- Laboratory of Pharmaceutical Technology, School of Pharmacy, Universidade Federal de Goiás (UFG), Goiânia, GO, Brasil
| | - Lígia Marquez Andrade
- Laboratory of Pharmaceutical Technology, School of Pharmacy, Universidade Federal de Goiás (UFG), Goiânia, GO, Brasil
| | - Fernando Augusto Pires de Sá
- Laboratory of Food, Drugs and Cosmetics (LTMAC), Universidade de Brasília (UnB), Campus Universitário Darcy Ribeiro, Asa Norte, 70.910-900, Brasíl, Brasíl, DF, Brasil
| | - Ricardo Neves Marreto
- Laboratory of Pharmaceutical Technology, School of Pharmacy, Universidade Federal de Goiás (UFG), Goiânia, GO, Brasil
| | - Eliana Martins Lima
- Laboratory of Pharmaceutical Technology, School of Pharmacy, Universidade Federal de Goiás (UFG), Goiânia, GO, Brasil
| | - Tais Gratieri
- Laboratory of Food, Drugs and Cosmetics (LTMAC), Universidade de Brasília (UnB), Campus Universitário Darcy Ribeiro, Asa Norte, 70.910-900, Brasíl, Brasíl, DF, Brasil
| | - Stephânia Fleury Taveira
- Laboratory of Pharmaceutical Technology, School of Pharmacy, Universidade Federal de Goiás (UFG), Goiânia, GO, Brasil
| |
Collapse
|
21
|
Yan HM, Song J, Zhang ZH, Jia XB. Optimization and anticancer activity in vitro and in vivo of baohuoside I incorporated into mixed micelles based on lecithin and Solutol HS 15. Drug Deliv 2015; 23:2911-2918. [PMID: 26644047 DOI: 10.3109/10717544.2015.1120365] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Baohuoside I, extracted from the Herba epimedii, is an effective but a poorly soluble antitumor drug. To improve its solubility, formulation of baohuoside I-loaded mixed micelles with lecithin and Solutol HS 15 (BLSM) has been performed in this study. We performed a systematic comparative evaluation of the antiproliferative effect, cellular uptake, antitumor efficacy, and in vivo tumor targeting of these micelles using non-small cell lung cancer (NSCLC) A549 cells. Results showed that the obtained micelles have a mean particle size of around 62.54 nm, and the size of micelles was narrowly distributed. With the improved cellular uptake, BLSM displayed a more potent antiproliferative action on A549 cell lines than baohuoside I; half-maximal inhibitory concentration (IC50) was 6.31 versus 18.28 µg/mL, respectively. The antitumor efficacy test in nude mice showed that BLSM exhibited significantly higher antitumor activity against NSCLC with lesser toxic effects on normal tissues. The imaging study for in vivo targeting demonstrated that the mixed micelles formulation achieved effective and targeted drug delivery. Therefore, BLSM might be a potential antitumor formulation.
Collapse
Affiliation(s)
- Hong-Mei Yan
- a Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine , Nanjing , China and.,b Key Laboratory of New Drug Delivery System of Chinese Materia Medica, Jiangsu Provincial Academy of Chinese Medicine , Nanjing , China
| | - Jie Song
- a Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine , Nanjing , China and.,b Key Laboratory of New Drug Delivery System of Chinese Materia Medica, Jiangsu Provincial Academy of Chinese Medicine , Nanjing , China
| | - Zhen-Hai Zhang
- b Key Laboratory of New Drug Delivery System of Chinese Materia Medica, Jiangsu Provincial Academy of Chinese Medicine , Nanjing , China
| | - Xiao-Bin Jia
- a Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine , Nanjing , China and.,b Key Laboratory of New Drug Delivery System of Chinese Materia Medica, Jiangsu Provincial Academy of Chinese Medicine , Nanjing , China
| |
Collapse
|
22
|
Eroğlu İ, Azizoğlu E, Özyazıcı M, Nenni M, Gürer Orhan H, Özbal S, Tekmen I, Ertam İ, Ünal İ, Özer Ö. Effective topical delivery systems for corticosteroids: dermatological and histological evaluations. Drug Deliv 2014; 23:1502-13. [PMID: 25259424 DOI: 10.3109/10717544.2014.960981] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Atopic dermatitis (AD) is a chronic and relapsing skin disease with severe eczematous lesions. Long-term topical corticosteroid treatment can induce skin atrophy, hypopigmentation and transepidermal water loss (TEWL) increase. A new treatment approach was needed to reduce the risk by dermal targeting. For this purpose, Betamethasone valerate (BMV)/Diflucortolone valerate (DFV)-loaded liposomes (220-350 nm) were prepared and incorporated into chitosan gel to obtain adequate viscosity (∼13 000 cps). Drugs were localized in stratum corneum + epidermis of rat skin in ex-vivo permeation studies. The toxicity was assessed on human fibroblast cells. In point of in-vivo studies, pharmacodynamic responses, treatment efficacy and skin irritation were evaluated and compared with previously prepared nanoparticles. Liposome/nanoparticle in gel formulations produced higher paw edema inhibition in rats with respect to the commercial cream. Similar skin blanching effect with commercial creams was obtained via liposome in gels although they contain 10 times less drug. Dermatological scoring results, prognostic histological parameters and suppression of mast cell numbers showed higher treatment efficiency of liposome/nanoparticle in gel formulations in AD-induced rats. TEWL and erythema measurements confirmed these results. Overview of obtained results showed that liposomes might be an effective and safe carrier for corticosteroids in skin disease treatment.
Collapse
Affiliation(s)
| | | | | | - Merve Nenni
- b Department of Pharmaceutical Toxicology, Faculty of Pharmacy , Ege University , Bornova, Izmir , Turkey
| | - Hande Gürer Orhan
- b Department of Pharmaceutical Toxicology, Faculty of Pharmacy , Ege University , Bornova, Izmir , Turkey
| | - Seda Özbal
- c Department of Histology and Embryology, Faculty of Medicine , Dokuz Eylul University , Inciralti, Izmir , Turkey , and
| | - Işıl Tekmen
- c Department of Histology and Embryology, Faculty of Medicine , Dokuz Eylul University , Inciralti, Izmir , Turkey , and
| | - İlgen Ertam
- d Department of Dermatology, Faculty of Medicine , Ege University , Bornova, Izmir , Turkey
| | - İdil Ünal
- d Department of Dermatology, Faculty of Medicine , Ege University , Bornova, Izmir , Turkey
| | - Özgen Özer
- a Department of Pharmaceutical Technology
| |
Collapse
|
23
|
Abdel-Mottaleb MMA, Try C, Pellequer Y, Lamprecht A. Nanomedicine strategies for targeting skin inflammation. Nanomedicine (Lond) 2014; 9:1727-43. [DOI: 10.2217/nnm.14.74] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Topical treatment of skin diseases is an attractive strategy as it receives high acceptance from patients, resulting in higher compliance and therapeutic outcomes. Recently, the use of variable nanocarriers for dermal application has been widely explored, as they offer several advantages compared with conventional topical preparations, including higher skin penetration, controlled and targeted drug delivery and the achievement of higher therapeutic effects. This article will focus on skin inflammation or dermatitis as it is one of the most common skin problems, describing the different types and causes of dermatitis, as well as the typical treatment regimens. The potential use of nanocarriers for targeting skin inflammation and the achievement of higher therapeutic effects using nanotechnology will be explored.
Collapse
Affiliation(s)
- Mona MA Abdel-Mottaleb
- Laboratory of Pharmaceutical Engineering & Biopharmaceutics, EA4267, University of Franche-Comté, Besançon, France
- Department of Pharmaceutics & industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
| | - Celine Try
- Laboratory of Pharmaceutical Engineering & Biopharmaceutics, EA4267, University of Franche-Comté, Besançon, France
- Clinical Investigation Center (Inserm CIC 1431), Regional University Hospital of Besançon, Besançon, France
| | - Yann Pellequer
- Laboratory of Pharmaceutical Engineering & Biopharmaceutics, EA4267, University of Franche-Comté, Besançon, France
| | - Alf Lamprecht
- Laboratory of Pharmaceutical Engineering & Biopharmaceutics, EA4267, University of Franche-Comté, Besançon, France
- Laboratory of Pharmaceutical Technology & Biopharmaceutics, University of Bonn, Bonn, Germany
| |
Collapse
|